51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo
Recommended Citation
Hamzavi I, Soliman AM, Camp HS, Ladd M, Pokrzywinski R, Sen R, Schlosser BJ, Min Bae J, Ezzedine K. 51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo. J Am Acad Dermatol 2024; 91(3):AB297.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Facial-Vitiligo Area Scoring Index (F-VASI) and Total-VASI (T-VASI) are clinician-reported outcomes that quantify depigmentation. The reliability, validity, responsiveness, and clinically meaningful score difference for VASI are not fully characterized. Using data from a phase 2, randomized, double-blind, placebo-controlled study (NCT04927975), of upadacitinib (6, 11, or 22 mg) vs placebo for 24 weeks, we evaluated the psychometric characteristics of F-VASI and T-VASI. Analyses included data from 164 patients. Test-retest reliability was excellent for F-VASI (ICC=0.99) and T-VASI (ICC=0.98) when comparing patients with clinically stable vitiligo (no change in Face-Physician Global Vitiligo Assessment [F-PhGVA; n=124] or Total-Physician Global Vitiligo Assessment [T-PhGVA; n=115] between baseline and week 4). At baseline and week 24, F-VASI and T-VASI had moderate-to-strong correlations with F-PhGVA (Spearman’s r=0.65–0.71) and T-PhGVA (r=0.63–0.65), respectively. Average F-VASI and T-VASI scores at baseline and week 24 decreased with increasing re-pigmentation levels (defined by F-PhGVA and T-PhGVA, respectively). F-VASI and T-VASI were responsive; least-square means at week 24 indicated greater F-VASI and T-VASI improvement with greater PhGIC-V improvement. Significant differences between F-VASI (P<.0001) and T-VASI (P<.001) were detected among patients with improvement in PhGIC-V vs those with no change or worsened PhGIC-V. At week 24, thresholds of 50% and 30% improvement from baseline in F-VASI (F-VASI 50) and T-VASI (T-VASI 30), respectively, reflected meaningful score improvements (lower than commonly used thresholds of T-VASI 50 and F-VASI 75). These results demonstrate that F-VASI and T-VASI are reliable, valid, able to differentiate between clinically distinct groups, and responsive to improvements in vitiligo involvement.
Volume
91
Issue
3
First Page
AB297
